Diego A.S. Toesca

Dr. Diego A.S. Toesca


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Advances in Radiation Oncology
Verified
Journal Article
Open access
DTDiego A.S. Toesca
Diego A.S. Toesca
AKAmanda J. Koong
Amanda J. Koong
RERie von Eyben
Rie von Eyben
AKAlbert C. Koong
Albert C. Koong
DCDaniel T Chang
Daniel T Chang
This study aimed to report on our institutional experience in the use of stereotactic body radiation therapy (SBRT) for the treatment of adrenal gland metastases. Specifically, we examined the outcomes and toxicity from this treatment modality on adjacent organs at risk. Data were retrieved from patients with adrenal metastases who were treated with SBRT between 2008 and 2017. Patients with primary adrenal malignancies were excluded. Toxicities were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03. Time-to-event rates were calculated from the date of SBRT delivery. In total, 35 patients with adrenal metastases were identified. Four patients were treated for bilateral disease. The median dose was 40 Gy (range, 20-54 Gy) in 5 fractions (range, 1-6 fractions). The median follow-up time was 37 months (range, 14-451 months) from disease diagnosis and 7 months (range, 1-54 months) from the SBRT start date. With death treated as a competing risk event, the cumulative incidence of local failure was 7.6% at 1 year after SBRT and 19.2% at 3 years. The median overall survival (OS) time was 19 months (95% confidence interval, 8-54 months) and tumor size correlated with survival (P = .0006). Patients with metastases <2.9 cm had a median OS of 54 months compared with 11 months for those with adrenal metastases ≥2.9 cm (P = .01). Incidence of grade 2 toxicity was 17% with no case of grade ≥3 toxicity. SBRT did not impact renal function with a mean estimated decline in glomerular filtration rate of only 2.6 ± 8 mL/min/1.73 m2 compared with baseline. Combined kidneys V5 and combined renal cortex V17.5 did not correlate with a change in estimated glomerular filtration rate (P = .7 and P = .9, respectively). SBRT offers excellent local control for the treatment of adrenal gland metastases with very low toxicity rates and no significant short-term impact on renal function.

1 November 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DTDiego A.S. Toesca
Diego A.S. Toesca
FAFaisal Ahmed
Faisal Ahmed
MKMehr Kashyap
Mehr Kashyap
JBJ Richelcyn M. Baclay
J Richelcyn M. Baclay
RERie von Eyben
Rie von Eyben
DCDaniel T Chang
Daniel T Chang

1 July 2020 in Practical Radiation Oncology
Verified
Journal Article
Closed access
AKAmanda J. Koong
Amanda J. Koong
DTDiego A.S. Toesca
Diego A.S. Toesca
JBJ. Richelcyn M. Baclay
J. Richelcyn M. Baclay
EPErqi L. Pollom
Erqi L. Pollom
RERie von Eyben
Rie von Eyben
DCDaniel T Chang
Daniel T Chang

6 July 2024 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DTDiego A.S. Toesca
Diego A.S. Toesca
WHWilliam F. Hartsell
William F. Hartsell
TDTodd A. DeWees
Todd A. DeWees
JCJohn H. Chang
John H. Chang
BLBrady S. Laughlin
Brady S. Laughlin
CVCarlos E Vargas
Carlos E Vargas

23 December 2023 in Advances in Radiation Oncology
Verified
Journal Article
Open access
DTDiego A.S. Toesca
Diego A.S. Toesca
SCScott M. Cheney
Scott M. Cheney
PSParminder Singh
Parminder Singh
MSMelissa L. Stanton
Melissa L. Stanton
WWWilliam W. Wong
William W. Wong

25 February 2023 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
DTDiego A.S. Toesca
Diego A.S. Toesca
DCDaniel T. Chang
Daniel T. Chang